Our client company is seeking potential partner companies to further develop or co-develop it's recently discovered GABA compounds.
The clinical compounds are based around GABA (gamma aminobutyric acid) which is an important amino acid which functions as the most prevalent inhibitory neurotransmitter in the central nervous system. At present they exhibit promising potential as neuropathic pain compounds without CNS-related side effects which are common with these types of pain treatments.
Partner companies to be considered by the client will be those who are based within the pain/chronic pain field. The companies should also be capable of carrying out early stage clinical development of the compounds with or without the co-operation of the client company.
These compounds represent an excellent opportunity for the right partner company with the appropriate clinical development expertise as the CNS/pain markets remain still relatively untapped. With patent expirations on the horizon the established products (accounting for approx 75% of pain market) will soon be susceptible to generic and new product competition. With over 200 drugs in clinical development the pain market looks set to continue as one of the Life Science industry's targets for finding effective treatment.